Experience

IGM Biosciences – $201 Million IPO

September 18, 2019

Cooley advised underwriters on IGM Biosciences’ $201.3 million initial public offering of 12,578,125 shares of common stock, including full exercise of the underwriters’ option to purchase additional shares. Jefferies, Piper Jaffray, Stifel, Nicolaus & Company and Guggenheim Securities acted as joint book-running managers for the offering. IGM Biosciences’ securities now trade on the Nasdaq Global Select Market under the symbol “IGMS.” Partners Jonie Kondracki, Charlie Kim, Dave Peinsipp and Will Cai led the Cooley team.

Related contacts

Jonie Ing Kondracki
Partner, San Francisco
Charlie Kim
Partner, San Diego
David Peinsipp
Partner, San Francisco
Will Cai
Partner, Hong Kong
Daniel Hutchins
Associate, Santa Monica

Related Practices & Industries

Atreca - $125 Million IPO

June 20, 2019

Cooley advised Atreca on its $125 million initial public offering of 7,350,000 shares of common stock. Atreca, whose securities now trade on the Nasdaq Global Select Market under the symbol “BCEL,” is a biopharmaceutical company using a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. Partners Barbara Kosacz, Danielle Naftulin and Mike Tenta led the Cooley team.

Related contacts

Daniel Hutchins
Associate, Santa Monica

Related Practices & Industries

AbCellera Biologics - $556 million IPO

Cooley advised the underwriters on AbCellera Biologic’s $556 million initial public offering of 27,772,500 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Credit Suisse Securities (USA) LLC, Stifel, Nicolaus & Company, Incorporated, Berenberg Capital Markets LLC, SVB Leerink LLC and BMO Capital Markets Corp. acted as the joint book-running managers for the offering. AbCellera Biologics, whose securities now trade on the Nasdaq Global Market under the symbol “ABCL,” is a technology company that aims to become the centralized operating system for next-generation antibody discovery. Partners Charlie Kim, Kristin VanderPas, Div Gupta and Rich Segal led the Cooley team.

Related contacts

Charlie Kim
Partner, San Diego
Kristin VanderPas
Partner, San Francisco
Div Gupta
Partner, New York
Richard Segal
Partner, New York
Denny Won
Partner, San Francisco
Daniel Hutchins
Associate, Santa Monica
Dr. Xiaozhen (Shawn) Yu
Partner, Washington, DC

Related Practices & Industries

Admissions and credentials

California

State of Washington

US Patent and Trademark Office

Memberships and affiliations

Seattle IP American Inn of Court

Washington State Patent Law Association

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.